Financial Data and Key Metrics Changes - The company achieved sales of $5.9 billion in the first quarter, exceeding guidance and reflecting a 5% increase year-over-year and sequentially [4][10] - Adjusted EPS was $0.84, near the high end of guidance [4] - Gross margin for the quarter was 10.4%, down 42 basis points year-over-year and 15 basis points sequentially [10][11] - Adjusted operating income was $151 million, with an adjusted operating margin of 2.6% [12] Business Line Data and Key Metrics Changes - Electronic components sales increased by 5% year-over-year and sequentially, driven by demand in Asia and the Americas [10][11] - Farnell sales grew by 50% year-over-year and 3% sequentially, with stable operating margins [10][11][12] - The IP&E segment showed steady sales with improving margins, particularly in Asia [7] Market Data and Key Metrics Changes - Sales in Asia grew by 10% year-over-year, representing over half of electronic components sales [10][11] - The Americas region saw a 3% year-over-year increase in sales, marking the first growth since fiscal 2023 [4][10] - EMEA sales were flat year-over-year and down 6% in constant currency [10] Company Strategy and Development Direction - The company is focused on balancing growth opportunities with inventory optimization [5][14] - There is an emphasis on enhancing digital capabilities and leveraging the core ecosystem for new opportunities, particularly in Farnell [7] - The company aims to reduce leverage to approximately 3.0 times over the next year while maintaining a strong balance sheet [16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about recovery in Asia and progress in the Americas, with stabilizing conditions in EMEA [8][9] - There are positive signs from supplier partners regarding lead times and potential price increases, indicating a strengthening market [9][33] - The company anticipates modest growth in the December quarter, particularly in Europe, as bookings have improved [29] Other Important Information - The company increased its quarterly dividend by approximately 6% to $0.35 per share [16] - The company repurchased approximately 2.6 million shares, totaling $138 million, representing 3% of outstanding shares in the first quarter [16] Q&A Session Summary Question: Exposure to AI applications in data centers - Management indicated that exposure to hyperscalers is relatively small, around 7% of Asia-Pac business, with opportunities in storage, connectivity, and power [19][20] Question: Inventory days and cash flow expectations - Management noted that inventory days decreased slightly, with expectations for further declines as sales grow [21][22][24] Question: Demand profile for EMEA in December quarter - Management expects modest growth in EMEA, indicating that the region is hitting the bottom after a tough period [29] Question: Incremental margins and operating leverage - Management indicated that the return to year-over-year growth in total business should provide operating leverage and expand margins [30][31] Question: Potential price increases from suppliers - Management noted that certain technologies are seeing potential price increases, particularly in memory and interconnect products [32][33] Question: Core segment margins and future expectations - Management expressed cautious optimism about achieving core margins above 4% in fiscal 2026, depending on mix shifts and market recovery [38][39] Question: Farnell margins and revenue impacts - Management indicated that Farnell margins could continue to grow, but product mix will play a significant role [41][43]

Financial Data and Key Metrics Changes - The company reported a same-store NOI growth of 8.2%, with the street retail portfolio delivering 13% growth during the quarter [27][28] - The quarterly FFO increased to $0.29 compared to $0.28 in the previous quarter, despite short-term dilution from the City Point loan conversion [34][35] - The company maintained its FFO guidance for 2026, moving to a simplified reporting metric that excludes investment management gains [36][37] Business Line Data and Key Metrics Changes - The company executed $3.7 million in new leases during the third quarter, bringing total signed leases year-to-date to $11.4 million [16][21] - The average GAAP spread for new and renewal leases was 32%, with a notable 36% spread in high-growth markets [16][18] - The leasing pipeline increased to $8 million, indicating strong tenant demand and leasing velocity [16][21] Market Data and Key Metrics Changes - Sales in SoHo increased by 15%, Bleecker Street by over 30%, and the Gold Coast of Chicago by over 40% year-to-date [21][22] - Despite concerns in Washington, DC, sales on M Street rose by 16% year-over-year, showcasing resilience in urban markets [22] - The company noted a resurgence in foot traffic and consumer spending, particularly among affluent consumers, driving demand for street retail [6][9] Company Strategy and Development Direction - The company aims to become the premier owner-operator of street retail in the U.S., focusing on internal growth and external acquisitions [12][13] - The strategy includes enhancing the leasing portfolio in key urban markets and capitalizing on the demand for direct-to-consumer retail locations [6][12] - The company is confident in its ability to invest accretively despite rising costs of capital, leveraging its reputation as a buyer of choice in the street retail space [11][12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the ongoing recovery in consumer spending, particularly among affluent consumers, which is expected to continue driving demand for retail space [46][47] - The company anticipates achieving 10% REIT portfolio NOI growth in 2026, supported by strong internal growth and a robust acquisition pipeline [33][38] - Management acknowledged the importance of adapting to market conditions and maintaining flexibility in funding strategies to support growth initiatives [64][66] Other Important Information - The company has raised approximately $212 million in equity to fund its acquisition pipeline and redevelopment projects [38] - The investment management platform is seeing increased interest from institutional investors, indicating a strong demand for retail assets [70] - The company is focused on simplifying its financial reporting to provide clearer insights into its core operating results [27][36] Q&A Session Summary Question: Can you provide details on the acquisition pipeline? - Management indicated that the $500 million pipeline is gross and includes specific negotiations, with a focus on street retail opportunities [56][57] Question: Are you seeing signs of slowing tenant demand? - Management confirmed strong tenant demand, driven by affluent consumers and the shift towards direct-to-consumer retail strategies [46][47] Question: What factors will influence the 5% to 9% same-store growth range in 2026? - Management highlighted that achieving the higher end of the range depends on the speed of leasing and market conditions, with confidence in surpassing 5% growth [51] Question: How is the company managing its balance sheet for future investments? - Management emphasized maintaining a pro-rata debt to EBITDA ratio and leveraging both equity and debt markets to fund acquisitions [64][66] Question: What is the level of demand from institutional partners for the investment management platform? - Management reported broad demand from institutional investors seeking retail opportunities, indicating a strong interest in partnering [70]

Financial Data and Key Metrics Changes - The company reported Q3 AFO of $0.45 per share, a 3% increase from Q3 last year [17] - Q3 cash rental income was $66.1 million, representing a growth of 12.6% compared to the same quarter last year [18] - Annualized cash-based rent for leases in place as of quarter end is $255.6 million, with a weighted average five-year annual cash rent escalator of 1.4% [18] Business Line Data and Key Metrics Changes - The company acquired 28 properties in Q3 for $82 million at a blended cap rate of 6.8%, with a weighted average lease term of 12 years [10] - Over the first 10 months of 2025, the company acquired 77 properties for $229 million, also at a blended 6.8% cap rate [10] - The in-place portfolio has zero exposure to problem retailers or sectors, maintaining a rent coverage of 5.1 times for the majority of the portfolio [6][18] Market Data and Key Metrics Changes - The company has diversified its rent sources, with Olive Garden and LongHorn Steakhouse now accounting for 32% and 9% of rent, respectively, down from a combined 94% at spin-off [8] - 35% of rents now come from sectors outside of casual dining, including automotive service (13%), quick service restaurants (11%), and medical retail (10%) [8] Company Strategy and Development Direction - The company aims to continue its acquisition strategy while maintaining a focus on quality tenants and properties, avoiding sacrificing quality for volume [5] - The company has a strong competitive advantage in its ability to modulate acquisition pace based on the cost of capital [5] - The company is well-positioned with $270 million in combined dry powder to fuel growth before reaching a mid-five times leverage target [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the current acquisition pipeline and the improved debt market, indicating a favorable environment for growth [9][28] - The company has maintained a strong balance sheet with a net debt to Adjusted EBITDA ratio of 4.7 times, near a seven-year low [16] - Management noted that the portfolio remains resilient, with strong occupancy and collection rates, and low bad debt expense [56] Other Important Information - The company has implemented a new disclosure on its website, providing a full list of properties with detailed data to enhance transparency for investors [20] - The company has a healthy fixed charge coverage ratio of 4.7 times and no debt maturities until the end of 2026 [17] Q&A Session Summary Question: On underwriting standards and potential adjustments - Management indicated that they do not foresee lowering their strict underwriting standards, emphasizing the importance of maintaining a high-quality portfolio [23] Question: Funding pipeline with remaining forward equity - Management clarified that the remaining $100 million in forward equity, combined with $170 million in debt capacity and retained cash flow, provides substantial acquisition capacity [24] Question: Assessment of the acquisition environment - Management expressed a favorable view of the current acquisition environment, noting a capable team and a strong balance sheet to support accretive acquisitions [28] Question: Confidence in Darden lease renewals - Management expects very high renewal rates for Darden leases, citing strong coverage and the value of their menu offerings [30] Question: Competition in the net lease sector - Management acknowledged increased competition from private equity but emphasized their diverse sourcing strategy, which includes both large portfolios and smaller acquisitions [45]

Financial Data and Key Metrics Changes - In Q3 2025, total revenue was just over $1 billion, reflecting a year-over-year increase of approximately 2% on both a reported and core basis [11] - Adjusted EBITDA grew by 10% year-over-year to $309 million, with an adjusted EBITDA margin expanding by approximately 200 basis points to 30% [12] - Adjusted EPS was $0.68, up 15% year-over-year, driven by growth in adjusted EBITDA and favorable interest expense on lower debt balances [12][19] Business Line Data and Key Metrics Changes - Intelligent Operating Solutions (iOS) segment revenue grew just over 2.5% on a reported basis, with core revenue growth at 2% [14] - Advanced Healthcare Solutions (AHS) segment revenue was $328 million, growing approximately 2% year-over-year, with adjusted EBITDA margin expanding from roughly 27% to 28% [17] Market Data and Key Metrics Changes - North America showed solid growth, improving sequentially from Q2, driven by strengthening demand trends for professional instrumentation and healthcare equipment [11] - Europe experienced a year-over-year decline, worsened modestly from Q2 due to weakening macro conditions [11] - The rest of the world showed mixed results, with significant acceleration in South Asia, particularly India, which is expected to drive strong momentum in the coming years [9] Company Strategy and Development Direction - The company is focused on driving profitable organic growth through its Fortive Business System, with a strategy centered on innovation acceleration, commercial acceleration, and recurring customer value [6][24] - Capital allocation priorities include investing in organic growth, pursuing accretive bolt-on M&A, returning capital through share repurchases, and maintaining a modest growing dividend [10][39] - The company is committed to maximizing medium to long-term shareholder returns and has demonstrated this through significant share repurchases [5][18] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's growth trajectory, emphasizing the importance of customer-centric operations and the simplification of the organizational model [22][23] - The company expects overall core growth to moderate in Q4, with AHS core growth broadly in line with Q3 levels and very modest core growth at iOS [19][95] - Management remains confident in the healthcare market's resilience, citing aging demographics and increasing healthcare needs as long-term growth drivers [97] Other Important Information - The company successfully completed the spin-off of its Precision Technologies segment, now operating independently as Rallian, on June 28, 2025 [2] - Free cash flow for Q3 was $266 million, with trailing twelve-month free cash flow growing to $922 million [13][18] Q&A Session Summary Question: Margin performance and Q4 guidance - Management noted that Q3 margin performance was driven by revenue performance and cost discipline, with expectations to maintain cost discipline while reinvesting some resources in Q4 [31][32] Question: Impact of government shutdown on performance - The company indicated that its exposure to federal government funding is minimal, and the shutdown has not significantly impacted performance [34] Question: Capital allocation and buyback strategy - Management explained that the $1 billion share repurchase was based on strong free cash flow and attractive valuations, with a focus on smaller bolt-on acquisitions for growth [38][39] Question: Demand trends in AHS segment - Management reported sequential improvement in demand for healthcare capital equipment and consumables, driven by more certainty in legislative conditions [52] Question: Tax rate outlook - The CFO indicated that a mid-teens tax rate is a good framework for modeling through 2026, with potential risks from new proposals [53] Question: Demand by region - North America continues to perform strongly, while Western Europe remains soft, with mixed results in other regions [69]

Financial Data and Key Metrics Changes - Third quarter reported earnings were $133 million, or $0.32 per share, while adjusted earnings were $1 billion, or $2.52 per share, reflecting a $52 million increase in total company adjusted earnings [10][11] - Generated $1.2 billion of operating cash flow, with operating cash flow excluding working capital at $1.9 billion [10][11] - Returned $751 million to shareholders, including $267 million in share repurchases, with a net debt to capital ratio of 41% [10][11] Business Line Data and Key Metrics Changes - Midstream results decreased mainly due to lower margins, partially offset by higher volumes [11] - Chemicals improved on higher margins and lower costs, with year-to-date adjusted Chemicals EBITDA at $700 million [3][11] - Refining results increased on stronger realigned margins, despite environmental costs associated with the Los Angeles Refinery [11] Market Data and Key Metrics Changes - In chemicals, global O&P utilization rate is expected to be in the mid-90% [12] - In refining, worldwide crude utilization rate is anticipated to be in the low to mid-90% [12] Company Strategy and Development Direction - The company is focused on integrating the Wood River, Borger, and Ponca City Refineries to capture operational and commercial synergies [4][8] - Aiming for an adjusted controllable cost per barrel of approximately $5.50 on an annual basis by 2027 [9] - The Western Gateway pipeline project is expected to enhance supply reliability to Arizona, California, and Nevada from Mid-Continent refineries [5][26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining high utilization rates due to long-term strategic decisions and reliability programs [56][58] - The company anticipates continued improvement in refining margins and operational efficiencies [11][81] Other Important Information - The acquisition of the remaining 50% interest in the Wood River and Borger Refineries simplifies the portfolio and enhances operational synergies [4][8] - The company is targeting a capital budget of approximately $2.5 billion, with a focus on low-capital, high-return projects [20][46] Q&A Session Summary Question: Discussion on WRB acquisition and synergies - Management highlighted the strategic importance of the Mid-Continent Central Corridor and the flexibility gained from full ownership of WRB, which opens up organic growth opportunities [15][16] Question: Rationale behind the Western Gateway project - Management explained that the project aims to leverage Mid-Continent strengths to meet growing demand in California, Arizona, and Nevada, amidst declining refining capacity in California [24][25] Question: Pathway to $17 billion debt target by 2027 - Management confirmed the commitment to reduce debt, projecting $1.5 to $2 billion available for debt reduction annually, supported by operating cash flow and asset dispositions [44][46][48] Question: Insights on refining margins and market conditions - Management noted expectations for widening light-heavy crude spreads and the impact of increased Canadian production on market dynamics [50][51] Question: Chemical segment performance and future outlook - Management indicated that CP Chem's margins improved due to a favorable feedstock blend and operational efficiencies, with expectations for continued strength in the chemical market [64][66]

Financial Data and Key Metrics Changes - In Q1 2026, the company originated $29.6 million in loans held for investment, a 1% increase from $29.4 million in the previous quarter [5] - Loan principal payments and payoffs decreased by 18% to $34.5 million from $42 million in the previous quarter [5] - Nonperforming assets increased to $1.9 million from $1.4 million in the previous quarter [6] - The allowance for credit losses to gross loans held for investment decreased to 56 basis points from 62 basis points [7] - Net interest margin increased by six basis points to 3% compared to 2.94% in the previous quarter [8] Business Line Data and Key Metrics Changes - Loans held for investment decreased by approximately $4 million, with declines in multifamily and commercial real estate loans, partially offset by an increase in single-family loans [6] - The weighted average rate of loans originated in September was 6.62%, compared to 5.2% for loans held for investment as of September 30, 2025 [9] Market Data and Key Metrics Changes - The company has approximately $107 million of loans repricing in December, expected to increase to a weighted average interest rate of 6.89% [10] - The average cost of deposits increased to 1.34%, while the cost of borrowing also increased to 4.59% [9] Company Strategy and Development Direction - The company is focusing on prudent adjustments to underwriting requirements to encourage higher loan origination volume [6] - The short-term strategy for balance sheet management is more growth-oriented than the previous fiscal year, with a disciplined loan growth approach [12] - The company aims to maintain cash dividends and has repurchased approximately 67,000 shares of common stock [13] Management's Comments on Operating Environment and Future Outlook - Management noted that real estate investors remain cautious due to market uncertainties, although there has been an increase in activity as mortgage interest rates decline [5] - The company expects modest or moderate net interest margin expansion in the upcoming quarters [20] - Management is optimistic about the potential for refinance activity due to declining mortgage interest rates [16] Other Important Information - Operating expenses remained unchanged at $7.6 million, representing a normalized run rate [12] - The company distributed $921,000 in cash dividends and repurchased approximately $1.1 million worth of common stock in the first quarter [14] Q&A Session Summary Question: Challenges in loan growth trajectory for 2026 - Management acknowledged hesitancy among borrowers in multifamily and commercial real estate due to higher mortgage rates, but noted that declining rates could present more opportunities [16] Question: Expectation for margin expansion - Management indicated that it is reasonable to expect margin expansion similar to the previous quarter, citing a growth in net interest margin from 2.74% to 3% over the past year [20] Question: Impact of lower interest rates on loan portfolio - Management explained that lower interest rates could lead to increased refinance activity, shortening the average life of the loan portfolio and potentially impacting credit loss provisions [22][24]

Financial Data and Key Metrics Changes - In Q3 2025, the company generated $157 million in revenue, a 17% increase year-over-year, and for the first nine months, revenue totaled $740 million, reflecting a 55% increase compared to the prior year [23][24] - TRYNGOLZA product sales reached $32 million, representing a nearly 70% increase over the second quarter [23][24] - Royalty revenues increased by approximately 13% to $76 million in Q3, driven by contributions from SPINRAZA and WAINUA [24] - The company raised its 2025 financial guidance, now expecting total revenue between $875 million and $900 million, an increase of $50 million from prior guidance [25][26] Business Line Data and Key Metrics Changes - TRYNGOLZA, the FDA-approved treatment for familial chylomicronemia syndrome, continues to show strong momentum with significant sales growth [5][14] - DAWNZERA, approved for hereditary angioedema, has seen strong early adoption, with initial prescriptions being filled shortly after approval [19][20] - The company anticipates two additional independent launches next year, with olzarsen for severe hypertriglyceridemia and zilganersen for Alexander disease [6][10] Market Data and Key Metrics Changes - The U.S. prophylactic HAE market is well established, with approximately 20% of patients switching treatments annually, indicating a significant opportunity for DAWNZERA [20] - The severe hypertriglyceridemia (sHTG) patient population is estimated to exceed 1 million in the U.S., with many patients struggling to manage triglyceride levels with current treatments [16][17] Company Strategy and Development Direction - The company is focused on executing its commercial strategy for TRYNGOLZA and DAWNZERA while preparing for upcoming launches of olzarsen and zilganersen [22][27] - The company aims to achieve cash flow breakeven by 2028, driving long-term value creation [26][27] - The commercial team is expanding outreach to healthcare providers and enhancing patient identification efforts to maximize the potential of its therapies [15][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued success of TRYNGOLZA and DAWNZERA, highlighting the strong early feedback from physicians and patients [19][20] - The company is optimistic about the upcoming data presentations and regulatory submissions, which are expected to further validate its pipeline and market potential [9][11] - Management emphasized the importance of addressing unmet needs in serious diseases and the potential for multi-billion dollar revenue from its pipeline [7][10] Other Important Information - The company announced the retirement of Richard Geary, Chief Development Officer, recognizing his contributions over the past 30 years [28] - The company is preparing for a significant data presentation at the American Heart Association (AHA) conference, which is expected to highlight the efficacy of olzarsen [38][39] Q&A Session Summary Question: What is the expected launch curve for olzarsen in sHTG? - The company anticipates strong interest from healthcare providers and plans to target approximately 20,000 HCPs covering around 360,000 patients with sHTG [31][33] Question: Any concerns regarding acute pancreatitis events in olzarsen studies? - Management expressed confidence in the groundbreaking results and emphasized that the data will be presented at AHA, with no significant concerns noted [37][38] Question: What are the peak revenue expectations for olzarsen and DAWNZERA? - Peak sales for DAWNZERA are expected to exceed $500 million, while olzarsen is anticipated to surpass $1 billion [39][40] Question: What is the pricing strategy for olzarsen? - The company is still evaluating pricing and will announce final pricing upon approval of the sHTG indication [44][45] Question: How is the early adoption of DAWNZERA progressing? - Early adoption is strong, with both switching patients and newly diagnosed patients starting treatment [72] Question: What is the source of revenue growth for WAINUA? - The revenue growth is primarily driven by new patient identification and the product's performance in improving quality of life [73]

Financial Data and Key Metrics Changes - In Q3 2025, the company generated $157 million in revenue, a 17% increase year over year, and for the first nine months, revenue totaled $740 million, reflecting a 55% increase compared to the prior year [23][24] - The company raised its 2025 financial guidance, now expecting total revenue between $875 million and $900 million, an increase of $50 million from previous guidance [25][26] - Operating loss is anticipated to be between $275 million and $300 million for the full year, with a cash balance expected to exceed $2.1 billion [25][26] Business Line Data and Key Metrics Changes - Tringolsa reported $32 million in net product sales, a nearly 70% increase quarter over quarter [14][23] - Royalty revenues increased by approximately 13% to $76 million in Q3, driven by contributions from Spinraza and Waylivra [24] - Donzera's launch is showing strong early adoption, with initial prescriptions being filled shortly after approval [19][20] Market Data and Key Metrics Changes - The U.S. prophylactic HAE market is well established, with approximately 20% of patients switching treatments annually, indicating a significant opportunity for Donzera [20] - The severe hypertriglyceridemia (SHTG) market is estimated to have over 1 million high-risk patients in the U.S., with Olzarsen positioned to address unmet needs in this population [16][17] Company Strategy and Development Direction - The company is focused on executing its strategy with two independent launches underway and plans for two additional launches next year [27][22] - The advancing wholly owned late-stage pipeline and a robust partnered portfolio are expected to drive sustained growth [7][26] - The company aims to achieve cash flow breakeven by 2028, emphasizing long-term value creation [26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued success of Tringolsa and the upcoming launches of Olzarsen and Zilganersen, highlighting the strong momentum across the business [5][27] - The management team is optimistic about the potential for multi-billion dollar revenue from the new product launches and the overall pipeline [7][25] Other Important Information - Richard Geary, Chief Development Officer, will retire at the end of the year, marking his last earnings call with the company [28] Q&A Session Summary Question: Thoughts on the launch curve for Olzarsen in SHTG - Management indicated strong interest from healthcare providers and plans to target approximately 20,000 HCPs covering around 360,000 patients [30][32] Question: Concerns regarding acute pancreatitis events in Olzarsen studies - Management reassured that the data is groundbreaking and that the acute pancreatitis outcomes will be detailed at the upcoming AHA presentation [36][38] Question: Peak revenue potential for Donzera and Olzarsen - Management expects peak sales for Donzera to exceed $500 million and for Olzarsen to exceed $1 billion [39] Question: Pricing strategy for Olzarsen - Management is still working on pricing and expects to provide more clarity next year [44][45] Question: Early prescriptions for Donzera - The launch is going well, with both switching patients and newly diagnosed patients contributing to early prescriptions [70][72]

Prosperity Bancshares (NYSE:PB) Q3 2025 Earnings Call October 29, 2025 11:30 AM ET Company ParticipantsAsylbek Osmonov - CFOKevin Hanigan - President and COOTim Timanus, Jr. - ChairmanBen Gerlinger - VP of Equity ResearchDavid Zalman - Senior Chairman and CEOMichael Rose - Managing Director of Equity ResearchJon Arfstrom - Associate Director of US ResearchCatherine Mealor - Managing DirectorCharlotte Rasche - SEVP and General CounselJared Shaw - Managing DirectorConference Call ParticipantsDave Rochester - ...

Financial Data and Key Metrics Changes - Gates reported third-quarter total sales of $856 million, translating to core growth of 1.7% year-over-year, with total revenues growing by 3% due to favorable foreign currency effects [9][10] - Adjusted EBITDA was $196 million, with an Adjusted EBITDA margin of 22.9%, representing a record margin for the third quarter and an increase of 90 basis points year-over-year [10][11] - Adjusted earnings per share increased by approximately 18% year-over-year to $0.39, driven by operating performance and a lower tax rate [11][12] - The net leverage ratio improved to 2.0 turns, a reduction of 0.4 turns compared to the previous year [7][16] Business Line Data and Key Metrics Changes - In the power transmission segment, revenues were $533 million with core growth of 2.3%, driven by personal mobility growth exceeding 20% [11][12] - The fluid power segment generated $322 million in sales, with core growth just under 1%, impacted by mid-teens decline in commercial on-highway sales [12][13] - Automotive replacement sales grew in the low single digits, while OEM sales were flat, reflecting mixed performance across different channels [10][11] Market Data and Key Metrics Changes - North American core sales were flat, with a low double-digit decline in industrial OEM sales due to demand weakness in agriculture and commercial on-highway [14][15] - EMEA saw core sales growth of 2.6%, with personal mobility growing almost 75% [15][16] - East Asia and India posted approximately 5% core growth, while South America experienced low to mid-single-digit declines [15][16] Company Strategy and Development Direction - The company is focused on restructuring plans, including closing multiple factories and implementing an ERP system conversion expected to be completed by mid-2026 [18][19] - The board approved a new $300 million share repurchase authorization, indicating a commitment to returning value to shareholders while maintaining flexibility for potential acquisitions [7][24] - The company anticipates achieving an Adjusted EBITDA margin of approximately 24% by the end of 2026, driven by ongoing cost optimization and strategic initiatives [22][24] Management's Comments on Operating Environment and Future Outlook - Management noted that while macro-industrial demand remains subdued, they are optimistic about stability and potential improvement in demand across most end markets by 2026 [9][23] - The company is experiencing uneven end market performance, with expectations for a gradual recovery in industrial demand [8][9] - Management expressed confidence in the growth potential of personal mobility and data center opportunities, projecting a compound annual growth rate of around 30% for personal mobility from 2025 to 2028 [36][38] Other Important Information - The company has updated its 2025 guidance, raising the adjusted EPS midpoint to $1.50 per share while slightly lowering the core sales growth outlook [7][17] - Free cash flow was reported at $73 million, representing a 73% conversion to adjusted net income, impacted by increased restructuring cash outflows [16][17] Q&A Session Summary Question: Clarification on margin targets and restructuring costs - Management confirmed that the 24% margin target for 2027 serves as a foundational floor, with expectations for growth in 2026 [29][30] - Additional costs related to restructuring and ERP implementation were discussed, with expectations for improved efficiencies post-implementation [32][33] Question: Growth visibility in personal mobility and data center markets - Management expressed optimism about personal mobility growth, projecting a 30% compound annual growth rate over the next three years [36][38] - The company is seeing increased design activity in liquid cooling for data centers, indicating strong future demand [38] Question: Impact of tariffs and volume expectations - Management noted a 30-40 basis point dilution in gross margins due to tariffs, but emphasized that the overall impact on EBITDA remains manageable [51][52] - There is cautious optimism regarding stabilization in agricultural markets and potential recovery in 2026 [53][54] Question: Insights on regional growth and market conditions - North America faces challenges in agriculture, while EMEA and Asia are showing positive growth trends, particularly in automotive replacement [85][88] - Management highlighted the potential for growth in South America and India as economic conditions improve [86][88]